DE68917061D1 - O-glycosylierter IGF-1. - Google Patents

O-glycosylierter IGF-1.

Info

Publication number
DE68917061D1
DE68917061D1 DE68917061T DE68917061T DE68917061D1 DE 68917061 D1 DE68917061 D1 DE 68917061D1 DE 68917061 T DE68917061 T DE 68917061T DE 68917061 T DE68917061 T DE 68917061T DE 68917061 D1 DE68917061 D1 DE 68917061D1
Authority
DE
Germany
Prior art keywords
igf
glycosylated
glycosylated igf
expressed
obtaining
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE68917061T
Other languages
English (en)
Other versions
DE68917061T2 (de
Inventor
Anna Dr Skottner-Lundin
Linda Dr Fryklund
Par Dr Gellerfors
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Health AB
Original Assignee
Pharmacia AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia AB filed Critical Pharmacia AB
Application granted granted Critical
Publication of DE68917061D1 publication Critical patent/DE68917061D1/de
Publication of DE68917061T2 publication Critical patent/DE68917061T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE68917061T 1988-08-20 1989-08-17 O-glycosylierter IGF-1. Expired - Fee Related DE68917061T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB888819826A GB8819826D0 (en) 1988-08-20 1988-08-20 Glycosylated igf-1

Publications (2)

Publication Number Publication Date
DE68917061D1 true DE68917061D1 (de) 1994-09-01
DE68917061T2 DE68917061T2 (de) 1994-11-17

Family

ID=10642464

Family Applications (1)

Application Number Title Priority Date Filing Date
DE68917061T Expired - Fee Related DE68917061T2 (de) 1988-08-20 1989-08-17 O-glycosylierter IGF-1.

Country Status (15)

Country Link
US (1) US5273966A (de)
EP (2) EP0360411B1 (de)
JP (1) JP2543998B2 (de)
AT (1) ATE109206T1 (de)
AU (1) AU623675B2 (de)
CA (1) CA1335802C (de)
DE (1) DE68917061T2 (de)
DK (1) DK175360B1 (de)
ES (1) ES2060778T3 (de)
FI (1) FI102282B (de)
GB (1) GB8819826D0 (de)
IE (1) IE65096B1 (de)
NO (1) NO180636C (de)
NZ (1) NZ230383A (de)
WO (1) WO1990002198A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8920381D0 (en) * 1989-09-08 1989-10-25 Greater Glasgow Health Board Treatment of insulin-resistant diabetes
US5612198A (en) * 1990-09-04 1997-03-18 The Salk Institute Production of insulin-like growth factor-1 in methylotrophic yeast cells
US5231178A (en) * 1991-01-16 1993-07-27 The Salk Institute Biotechnology/Industrial Associates, Inc. Method for the purification of intact, correctly-folded insulin-like growth factor-1
WO1992017595A1 (en) * 1991-04-01 1992-10-15 The Salk Institute Biotechnology/Industrial Associates, Inc. Genes which influence pichia proteolytic activity, and uses therefor
ES2097426T3 (es) * 1992-12-02 1997-04-01 Hoechst Ag Procedimiento para la obtencion de proinsulina con puentes de cistina correctamente unidos.
SE9402332D0 (sv) * 1994-07-01 1994-07-01 Pharmacia Ab Igf-1
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
SI2032155T1 (sl) * 2006-06-09 2015-04-30 Novartis Ag Stabilizirani polipeptidi inzulinu podobnega rastnega faktorja
EP2494050A4 (de) * 2009-10-30 2013-10-30 Merck Sharp & Dohme In glycoengineerter pichia pastoris hergestellter granulozytenkolonienstimulierender faktor
US20100172865A1 (en) * 2010-03-18 2010-07-08 Shantha Totada R Methods of enhancing hair growth
US9238080B2 (en) 2010-05-21 2016-01-19 Merrimack Pharmaceuticals, Inc. Bi-specific fusion proteins
CA2926173A1 (en) 2013-10-02 2015-04-09 Novartis Ag Insulin-like growth factor mimetics for use in therapy
WO2017059231A1 (en) 2015-10-02 2017-04-06 Silver Creek Pharmaceuticals, Inc. Bi-specific therapeutic proteins for tissue repair

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE95236T1 (de) * 1983-04-25 1993-10-15 Chiron Corp Hybrid-dns-synthesis von reifen insulinaehnlichen wachstumsfaktoren.

Also Published As

Publication number Publication date
EP0360411A1 (de) 1990-03-28
JPH05505514A (ja) 1993-08-19
GB8819826D0 (en) 1988-09-21
FI102282B1 (fi) 1998-11-13
FI910795A0 (fi) 1991-02-19
FI102282B (fi) 1998-11-13
DK175360B1 (da) 2004-09-13
EP0360411B1 (de) 1994-07-27
NO180636C (no) 1997-05-21
DE68917061T2 (de) 1994-11-17
NO910669D0 (no) 1991-02-19
NO180636B (no) 1997-02-10
DK29491D0 (da) 1991-02-20
AU4051889A (en) 1990-03-23
US5273966A (en) 1993-12-28
ATE109206T1 (de) 1994-08-15
ES2060778T3 (es) 1994-12-01
CA1335802C (en) 1995-06-06
IE892652L (en) 1990-02-20
NZ230383A (en) 1992-01-29
EP0429502A1 (de) 1991-06-05
AU623675B2 (en) 1992-05-21
WO1990002198A1 (en) 1990-03-08
NO910669L (no) 1991-02-19
DK29491A (da) 1991-04-19
JP2543998B2 (ja) 1996-10-16
IE65096B1 (en) 1995-10-04

Similar Documents

Publication Publication Date Title
DE69034091D1 (de) Herstellung von Hämoglobin und Analogen davon in Nicht-Erythrozytzellen
ATE122357T1 (de) Polypeptide mit hormonwachstumsbefreiender wirkung.
FI851336A0 (fi) Ny fysiologiskt aktiv human polypeptid.
ES2153444T3 (es) Anticuerpos contra interleucina-4 mamifera, y peptidos utiles como antigenos en su produccion.
ATE107513T1 (de) Stabilisierte formulierungen mit hydrohoben proteinen.
DE68917061D1 (de) O-glycosylierter IGF-1.
AU7184487A (en) Human g-csf protein expression
ATE358176T1 (de) Menschliche dnase
DE3689246D1 (de) Physiologisch aktives Polypeptid BUF-3.
DK0454898T3 (da) Glycosaminoglycan-modificeret protein, fremgangsmåde til fremstilling af proteinet, farmaceutiske præparater indeholdende proteinet samt anvendelse af proteinet
IT1232827B (it) Proteine biologicamente attive, formulazioni che le contengono e metodo per prepararle ed applicarle
DE3788004D1 (de) Verwendung von Tetrahydrocortisol in der Therapie von Glaukom.
DE3650790D1 (de) Menschlisches Interferon-Beta 2A zur Verwendung als Arzneimittel
ATE73462T1 (de) Hirudin-variante, deren verwendung und herstellung.
AU3902489A (en) Non-glycosylated, recombinant human IL2 in the reduced form, the process for obtaining it and its use as a medicament
AU3327789A (en) Expression of the hiv 24 kda 24 gag protein in methylotrophic yeast
SE8802685D0 (sv) Stol
ATE98217T1 (de) Terpen-amino-alkohole und deren medizinische verwendung.
IE891349L (en) EXPRESSION OF THE HIV kDa GAG PROTEIN IN YEAST

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee